Critical Outcome Technologies Inc. - Product Pipeline Review

Global Markets Direct’s, ‘Critical Outcome Technologies Inc. - Product Pipeline Review - 2016’, provides an overview of the Critical Outcome Technologies Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Critical Outcome Technologies Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Critical Outcome Technologies Inc.

The report provides overview of Critical Outcome Technologies Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Critical Outcome Technologies Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Critical Outcome Technologies Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Critical Outcome Technologies Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Critical Outcome Technologies Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Critical Outcome Technologies Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Critical Outcome Technologies Inc. Snapshot 5

Critical Outcome Technologies Inc. ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Critical Outcome Technologies Inc. Snapshot 5

Critical Outcome Technologies Inc. Overview 5

Key Facts 5

Critical Outcome Technologies Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Critical Outcome Technologies Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Critical Outcome Technologies Inc. - Pipeline Products Glance 11

Critical Outcome Technologies Inc. - Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

Critical Outcome Technologies Inc. - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

Critical Outcome Technologies Inc. - Drug Profiles 14

COTI-2 - Drug Profile 14

Product Description 14

Mechanism Of Action 14

R&D Progress 14

COTI-219 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

COTI-4 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

COTI-58 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Small Molecule for MRSA Infection - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Small Molecules for Acute Myelocytic Leukemia - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Small Molecules for Small Cell Lung Cancer - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecules to Antagonize VEGF-R and PDGF-R for Multiple Sclerosis - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Inhibit Angiogenesis for Undisclosed Indication - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecules to Inhibit CDKs for Colorectal Cancer - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Small Molecules to Inhibit Microtubulin for Colorectal Cancer - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecules to Inhibit Thymidylate Synthase and THFR for Colorectal Cancer - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Critical Outcome Technologies Inc. - Pipeline Analysis 36

Critical Outcome Technologies Inc. - Pipeline Products by Target 36

Critical Outcome Technologies Inc. - Pipeline Products by Route of Administration 37

Critical Outcome Technologies Inc. - Pipeline Products by Molecule Type 38

Critical Outcome Technologies Inc. - Pipeline Products by Mechanism of Action 39

Critical Outcome Technologies Inc. - Dormant Projects 40

Critical Outcome Technologies Inc. - Locations And Subsidiaries 41

Head Office 41

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

List of Tables

Critical Outcome Technologies Inc., Key Facts 5

Critical Outcome Technologies Inc. - Pipeline by Indication, 2016 8

Critical Outcome Technologies Inc. - ...

List of Tables

Critical Outcome Technologies Inc., Key Facts 5

Critical Outcome Technologies Inc. - Pipeline by Indication, 2016 8

Critical Outcome Technologies Inc. - Pipeline by Stage of Development, 2016 9

Critical Outcome Technologies Inc. - Monotherapy Products in Pipeline, 2016 10

Critical Outcome Technologies Inc. - Phase I, 2016 11

Critical Outcome Technologies Inc. - Preclinical, 2016 12

Critical Outcome Technologies Inc. - Discovery, 2016 13

Critical Outcome Technologies Inc. - Pipeline by Target, 2016 36

Critical Outcome Technologies Inc. - Pipeline by Route of Administration, 2016 37

Critical Outcome Technologies Inc. - Pipeline by Molecule Type, 2016 38

Critical Outcome Technologies Inc. - Pipeline Products by Mechanism of Action, 2016 39

Critical Outcome Technologies Inc. - Dormant Developmental Projects,2016 40

List of Figures

List of Figures

Critical Outcome Technologies Inc. - Pipeline by Top 10 Indication, 2016 7

Critical Outcome Technologies Inc. - Pipeline by Stage of Development, ...

List of Figures

Critical Outcome Technologies Inc. - Pipeline by Top 10 Indication, 2016 7

Critical Outcome Technologies Inc. - Pipeline by Stage of Development, 2016 9

Critical Outcome Technologies Inc. - Monotherapy Products in Pipeline, 2016 10

Critical Outcome Technologies Inc. - Pipeline by Top 10 Target, 2016 36

Critical Outcome Technologies Inc. - Pipeline by Route of Administration, 2016 37

Critical Outcome Technologies Inc. - Pipeline by Molecule Type, 2016 38

Critical Outcome Technologies Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 39

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports